Pharmaceuticals

10 Eli Lilly finance leaders

These ten Eli Lilly finance leaders, including Eli Lilly's CFO, have held finance roles covering Lilly Oncology, Global R&D, manufacturing, treasury and controllership. Readers can learn from them how finance teams at a pharmaceutical company plan budgets, fund research and manage capital.

10 professionals2 companiesData retrieved September 29, 2026

Professionals to explore

01—10
  1. Gordon Brooks

    LinkedIn

    Experience: Group Vice President - Controller and Corporate Strategy · Eli Lilly and Company

    Group Vice President - Controller and Corporate Strategy at Eli Lilly and Company since August 2024 (also March–June 2024), and Interim Chief Financial Officer from July to August 2024. Former Chief Procurement Officer (2022–2024) and Chief Procurement Officer and CFO Bio-Medicines (2019–2021) at Eli Lilly, and trained as a Chartered Accountant at Price Waterhouse.

  2. Helena Pécora

    LinkedIn

    Experience: Associate Vice President Manufacturing Finance · Eli Lilly and Company

    Associate Vice President Manufacturing Finance at Eli Lilly and Company since 2024, with a profile headline of Associate Vice President, Finance | CFO API & Dry Products Network. Former Associate Vice President & CFO Latin America Hub (2022–2024), CFO & BD Latin America, Sr Finance Director (2021–2022) and CFO Brazil, Finance Director (2017–2021) at Eli Lilly and Company.

  3. Ilissa Rassner

    LinkedIn

    Experience: CFO Lilly Cardiometabolic Health and Lilly Immunology · Eli Lilly and Company

    CFO Lilly Cardiometabolic Health and Lilly Immunology at Eli Lilly and Company since 2025. Former CFO, Eli Lilly Canada Inc. (2021–2025), CFO of Research and Development (2018–2021), Senior Director, Ethics & Compliance (2016–2018) and Director, Investor Relations (2011–2016) at Eli Lilly and Company.

  4. Jeff Utnage

    LinkedIn

    Experience: Vice President of Finance, Global Capital Controller · Eli Lilly and Company

    Vice President of Finance, Global Capital Controller at Eli Lilly and Company since 2024. Former Associate VP, Finance, Global Business Solutions (2019–2024), Senior Director, Global Manufacturing Procurement (2015–2019), Senior Director, Finance, Global Shared Services (2010–2015) and Senior Director and CFO, Lilly del Caribe (2007–2010) at Eli Lilly and Company.

  5. Jon Haug

    LinkedIn

    Experience: Treasurer and Corporate Finance Investment Banking · Eli Lilly and Company

    Treasurer and Corporate Finance Investment Banking at Eli Lilly and Company since 2024, with a profile headline of Sr Vice President, Treasurer and Corporate Finance Investment Banking. Former Vice President and CFO, Global Manufacturing and Quality (2019–2025), Vice President, CFO Manufacturing and Quality and Biomedicines (2018–2019), CFO UK and Northern Europe (2015–2019) and Assistant Treasurer (2013–2015) at Eli Lilly.

  6. Kay Flynn

    LinkedIn

    Experience: Senior Vice President Finance GBS - Global Business Solutions · Eli Lilly and Company

    Senior Vice President Finance GBS - Global Business Solutions at Eli Lilly and Company since 2019; her profile describes her leading Eli Lilly's global services organization in this role. Former Senior Director European Shared Services (2010–2019) and Finance Procurement Director - Manufacturing, Ireland (2004–2010) at Eli Lilly and Company.

  7. Lucas Montarce

    LinkedIn

    Experience: EVP and CFO · Eli Lilly

    EVP and CFO at Eli Lilly since September 2024, a role listed in the Finance & Accounting department at C-Level. The profile also lists a current President and General Manager role at Eli Lilly since February 2024, in the General Management department at President/Vice President level.

  8. Michael Thompson

    LinkedIn

    Experience: CFO Lilly Oncology & Lilly Neuroscience · Eli Lilly and Company

    CFO Lilly Oncology & Lilly Neuroscience at Eli Lilly and Company since 2025, listed at C-Level in Finance & Accounting. Former CFO Lilly Oncology (2024–2025), Associate Vice President Finance - Assistant Treasurer (2022–2024), CFO Lilly Austria & Switzerland and Director Lilly Export (2020–2022) and Director Eli Lilly Export (2020) at Eli Lilly and Company.

  9. Ping Fu

    LinkedIn

    Experience: CFO, Global Services Finance · Eli Lilly and Company

    CFO, Global Services Finance at Eli Lilly and Company since 2023, providing global financial controllership and budget oversight for cross-functional departments including finance, HR, legal and litigation. Former CFO Australia & New Zealand and North Asia Pacific Hub (2021–2023), CFO Korea (2018–2021), Finance Director Drug Product Manufacturing (2015–2018) and Taiwan CFO (2014–2015) at Eli Lilly.

  10. Todd Farnsworth

    LinkedIn

    Experience: Sr. VP and CFO of Global R&D and Immunology · Eli Lilly and Company

    Sr. VP and CFO of Global R&D and Immunology at Eli Lilly and Company since 2024. Former Sr. VP Corporate Strategy Transformation & CFO Loxo Lilly (2022–2024), CFO - Lilly Oncology (2015–2022), Sr. Finance Director - Corporate Financial Planning (2014–2015) and CFO Research (2012–2014) at Eli Lilly and Company.

Choose the right perspective

Match the person's finance area to your question, since business unit finance, treasury, controllership and manufacturing finance each answer different problems. For decisions that span countries or regions, favor someone whose roles have covered several markets or hubs.

Questions to take into the conversation

  1. 01How does a pharmaceutical finance team decide how much to invest in late-stage research programs versus commercial launches?
  2. 02What does finance need from manufacturing and quality leaders when planning large capacity investments?
  3. 03How do business unit CFOs balance company-wide targets with the needs of individual therapeutic areas?

About this directory

This is a professional research starting point based on business profile data retrieved on . Titles and companies reflect that source snapshot and may describe past or present roles. Check the linked profiles for current details. Inclusion does not imply Instant Expert membership or availability.

Request a correction or removal

Other perspectives in Pharmaceuticals